Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial.

被引：0
|
作者：
Oudard, Stephane
Hadaschik, Boris A.
Antoni, Laurent
Diels, Joris
Luccarini, Irene
Thilakarathne, Pushpike
Smith, Matthew Raymond
Small, Eric Jay
机构：
[1] Univ Paris, Georges Pompidou Hosp, Paris, France
[2] Univ Duisburg Essen, Essen, Germany
[3] Janssen Pharmaceut NV, Beerse, Belgium
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
157
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
    Feng, Felix Y.
    Thomas, Shibu
    Gormley, Michael
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Cheng, Shinta
    Ricci, Deborah S.
    Rooney, Oliver Brendan
    Mainwaring, Paul N.
    Olmos, David
    Saad, Fred
    Chowdhury, Simon
    Hadaschik, Boris A.
    Fishbane, Nicholas
    Davicioni, Elai
    Liu, Yang
    Small, Eric Jay
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation
    Mainwaring, P.
    Small, E.
    Uemura, H.
    Lee, J. Y.
    Pang, S-T.
    Marx, G.
    Kwon, T. G.
    Satoh, T.
    Bhaumik, A.
    Cheng, S.
    Londhe, A.
    Lopez-Gitlitz, A.
    Smith, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 68 - 68
  • [3] Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.
    Small, Eric Jay
    Saad, Fred
    Rathkopf, Dana E.
    Hadaschik, Boris A.
    Chowdhury, Simon
    Yu, Margaret K.
    Lopez-Gitlitz, Angela
    Rooney, Oliver Brendan
    Shu, Youyi
    Darif, Mohamed
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Androgen Receptor (AR) anomalies and efficacy of apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
    Mainwaring, Paul N.
    Smith, Matthew R.
    Thomas, Shibu
    Chowdhury, Simon
    Olmos, David
    Li, Jinhui
    Oudard, Siephane
    Feng, Felix Y.
    Gormley, Michael
    Ricci, Deborah S.
    Rooney, Brendan
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Small, Eric J.
    BJU INTERNATIONAL, 2018, 122 : 6 - 7
  • [5] EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOTHERAPY (XRT): POST HOC ANALYSIS OF SPARTAN
    Hadaschik, Boris A.
    Saad, Fred
    Graff, Julie N.
    Olmos, David
    Oudard, Stephane
    Mainwaring, Paul N.
    Uemura, Hiroji
    Lee, Ji Youl
    Lopez-Gitlitz, Angela
    Bhaumik, Amitabha
    Londhe, Anil
    Cheng, Shinta
    Todd, Mary B.
    Small, Eric J.
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2019, 201 (04): : E502 - E503
  • [6] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study
    Feng, Felix
    Thomas, Shibu
    Gormley, Michael
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Cheng, Shinta
    Ricci, Deborah S.
    Rooney, Brendan
    Mainwaring, Paul N.
    Olmos, David
    Saad, Fred
    Chowdhury, Simon
    Hadaschik, Boris
    Fishbane, Nick
    Davicioni, Elai
    Liu, Yang
    Small, Eric J.
    Smith, Matthew R.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
    Smith, Matthew R.
    Thomas, Shibu
    Chowdhury, Simon
    Olmos, David
    Li, Jinhui
    Mainwaring, Paul N.
    Oudard, Stephane
    Feng, Felix Y.
    Gormley, Michael
    Ricci, Deborah S.
    Rooney, Brendan
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Small, Eric J.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
    Smith, M. R.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B. A.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Uemura, H.
    De Porre, P.
    Smith, A.
    Zhang, K.
    Lopez-Gitlitz, A.
    Small, E. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 325 - 325
  • [9] SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Hadaschik, B. A.
    Small, E. J.
    Saad, F.
    Chowdhury, S.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Uemura, H.
    Lopez-Gitlitz, A.
    Trudel, G. C.
    Espina, B. M.
    Shu, Y.
    Park, Y. C.
    Rackoff, W. R.
    Yu, M. K.
    Smith, M. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 43 - 43
  • [10] Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Jay Small, Eric
    Saad, Fred
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris A.
    Graff, Julie N.
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    De Porre, Peter
    Smith, Andressa
    Doris Brookman-May, Sabine
    Li, Susan
    Zhang, Ke
    Brendan Rooney, Oliver
    Lopez-Gitlitz, Angela
    Raymond Smith, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345